Literature DB >> 28597359

Trends in prescribing rate of statins at discharge and modifiable factors in patients with atherosclerotic cardiovascular disease.

Bao-Tao Huang1, Yong Peng1, Fang-Yang Huang1, Tian-Li Xia1, Yi-Yue Gui1, Yan-Biao Liao1, Xiao-Bo Pu1, Shi-Jian Chen1, Yong Yang1, Mao Chen2.   

Abstract

Tremendous effort has been invested in reducing the prevalence of atherosclerotic cardiovascular disease (ASCVD) in China. Meanwhile, accumulating evidence has emerged to show the benefits of statins in the prevention of cardiovascular disease. The present study investigated the change trends of statins prescription at discharge among patients with ASCVD in recent years, differences across subtypes of ASCVD, and associated factors. The study included 51,972 patients with a discharge diagnosis of ASCVD who were hospitalized in West China Hospital from 2008 to 2014. Trends of statins prescription rates between subtypes of ASCVD were compared and potential influential factors were explored. The overall statins prescription rate in patients with ASCVD was 58.8%. Adjusted odds ratios (ORs) of increase in prescription rate per year were 1.15 (95% CI 1.13-1.17, p < 0.001), 1.14 (95% CI 1.10-1.17, p < 0.001), 1.19 (95% CI 1.16-1.23; p < 0.001), 1.14 (95% CI 1.09-1.19; p < 0.001), and 1.13 (95% CI 1.09-1.17; p < 0.001) for ASCVD, coronary artery disease, cerebrovascular disease, peripheral arterial disease (PAD), and polyvascular disease, respectively; no significant differences in trends were detected among ASCVD subtypes. However, statins prescription rates were persistently lower in cerebrovascular disease and PAD than the other two subtypes. Discharge departments, together with other physician-related and patient-related characteristics were associated with statins utilization. In conclusion, between 2008 and 2014, statins prescription rate in patients with ASCVD was not optimal. The increasing trends in statins prescription among patients with ASCVD subtypes were similar but the differences did not decrease. Consciousness of integrated and successive medical care should be strengthened in China.

Entities:  

Keywords:  Cardiovascular disease; Secondary prevention; Statins

Mesh:

Substances:

Year:  2017        PMID: 28597359     DOI: 10.1007/s11739-017-1694-9

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  25 in total

1.  Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry.

Authors:  Thomas M Maddox; P Michael Ho; Matthew Roe; David Dai; Thomas T Tsai; John S Rumsfeld
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-10-05

2.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

3.  Secondary prevention of ischemic stroke in urban China.

Authors:  Jade W Wei; Ji-Guang Wang; Yining Huang; Ming Liu; Yangfeng Wu; Lawrence K S Wong; Yan Cheng; En Xu; Qidong Yang; Hisatomi Arima; Emma L Heeley; Craig S Anderson
Journal:  Stroke       Date:  2010-03-11       Impact factor: 7.914

4.  Use of evidence-based therapies after discharge among elderly patients with acute myocardial infarction.

Authors:  Peter C Austin; Jack V Tu; Dennis T Ko; David A Alter
Journal:  CMAJ       Date:  2008-10-21       Impact factor: 8.262

5.  Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.

Authors:  Yufang Bi; Runlin Gao; Anushka Patel; Steve Su; Wei Gao; Dayi Hu; Dejia Huang; Lingzhi Kong; Wenhang Qi; Yangfeng Wu; Yuejin Yang; Fiona Turnbull
Journal:  Am Heart J       Date:  2008-12-17       Impact factor: 4.749

6.  Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

Authors:  Eva M Lonn; Jackie Bosch; Patricio López-Jaramillo; Jun Zhu; Lisheng Liu; Prem Pais; Rafael Diaz; Denis Xavier; Karen Sliwa; Antonio Dans; Alvaro Avezum; Leopoldo S Piegas; Katalin Keltai; Matyas Keltai; Irina Chazova; Ron J G Peters; Claes Held; Khalid Yusoff; Basil S Lewis; Petr Jansky; Alexander Parkhomenko; Kamlesh Khunti; William D Toff; Christopher M Reid; John Varigos; Lawrence A Leiter; Dora I Molina; Robert McKelvie; Janice Pogue; Joanne Wilkinson; Hyejung Jung; Gilles Dagenais; Salim Yusuf
Journal:  N Engl J Med       Date:  2016-04-02       Impact factor: 91.245

7.  Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

Authors:  Salim Yusuf; Jackie Bosch; Gilles Dagenais; Jun Zhu; Denis Xavier; Lisheng Liu; Prem Pais; Patricio López-Jaramillo; Lawrence A Leiter; Antonio Dans; Alvaro Avezum; Leopoldo S Piegas; Alexander Parkhomenko; Katalin Keltai; Matyas Keltai; Karen Sliwa; Ron J G Peters; Claes Held; Irina Chazova; Khalid Yusoff; Basil S Lewis; Petr Jansky; Kamlesh Khunti; William D Toff; Christopher M Reid; John Varigos; Gregorio Sanchez-Vallejo; Robert McKelvie; Janice Pogue; Hyejung Jung; Peggy Gao; Rafael Diaz; Eva Lonn
Journal:  N Engl J Med       Date:  2016-04-02       Impact factor: 91.245

8.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

9.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

10.  Association between statin use and short-term outcome based on severity of ischemic stroke: a cohort study.

Authors:  Bo Song; Yilong Wang; Xingquan Zhao; Liping Liu; Chunxue Wang; Anxin Wang; Wanliang Du; Yongjun Wang
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more
  2 in total

1.  Suboptimal use of statins for secondary cardiovascular prevention: a "planetary" issue.

Authors:  Alfonso Bellia; David Della-Morte; Davide Lauro
Journal:  Intern Emerg Med       Date:  2017-09-14       Impact factor: 3.397

2.  Management of peripheral arterial disease in the modern era: an internist "Cup of Tea".

Authors:  Marco Proietti
Journal:  Intern Emerg Med       Date:  2019-11-25       Impact factor: 3.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.